A condition that estimated to 33 million Americans are affected.

Although the prevalence increases with age, the problem affects people of all age groups. People with OAB often limit travel, social and even work activities potentially embarrassing episodes with this disease. With this disease. Millions of patients and their families to be by overactive by overactive bladder, it is important that we push the technology to new possibilities bring bring for people with overactive bladder to continue to manage it this condition, said Nancy Mueller, CEO, National Association for Continence.. OAB, a condition that estimated to 33 million Americans are affected, is caused by the premature contraction of the bladder muscles.

Cystic fibrosis , one of the most common inherited life-shortening diseases is by the production of thick, sticky mucus that eventually blocks the small airways, which characterizes to inflammation and infection. Mucus also affects the pancreatic ducts and prevents normal digestion and weight gain. Respiratory failure is the primary cause of early death. CF incidence runs from 1 in 2,000 to 1 in 3,200 live births.The medicine is already in the European Union in the European Union, when the regulatory authority has that the European Medicines Agency . The EMEA is permitted labeling carries information about the common adverse event that may occur from use of ATryn. These include dizziness, nausea, headache, bleeding, bleeding at the injection site and increased bleeding during treatment. GTC also warned that such with any intravenous protein products, allergic type hypersensitivity reactions are possible. . Sources: Reuters, GTC Biotherapeutics.Submitted by: Catharine Paddock.

An expert panel from United States Food U.S.S. Both companies plan to FDA approval for of ATryn in prevention and treatment of of venous thromboembolism in inherited antithrombin deficiency patients operated on and birth of A method, said a current message GTC.